These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38058141)

  • 1. Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States.
    Sandin R; Veenstra DL; Vankelegom M; Dzingina M; Sullivan SD; Campbell D; Ma C; Harrison C; Draica F; Wiemken TL; Mugwagwa T
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1290-1302. PubMed ID: 38058141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States.
    Carlson J; Foos V; Kasle A; Mugwagwa T; Draica F; Lee Wiemken T; Nguyen JL; Cha-Silva A; Migliaccio-Walle K; Dzingina M
    Value Health; 2024 Feb; 27(2):164-172. PubMed ID: 38043712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.
    Cha-Silva AS; Gavaghan MB; Bergroth T; Alexander-Parrish R; Yang J; Draica F; Patel J; Garner DA; Stanford RH; Meier G; McLaughlin JM; Nguyen JL
    Am J Ther; 2024 May-Jun 01; 31(3):e246-e257. PubMed ID: 38691664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
    J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 7. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
    Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
    J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    Chuang MH; Wu JY; Liu TH; Hsu WH; Tsai YW; Huang PY; Lai CC
    J Med Virol; 2023 Apr; 95(4):e28750. PubMed ID: 37185834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    Mazzotta V; Mazzaferri F; Lanini S; Mirandola M; Cozzi Lepri A; Vergori A; Savoldi A; Santoro A; Maccarrone G; Mastrorosa I; Simonetti O; Zottis F; Nicastri E; Rosini G; Rovigo L; Tavernaro L; Sarmati L; Tascini C; Girardi E; Cattelan AM; Antinori A; Tacconelli E;
    J Infect; 2024 Nov; 89(5):106294. PubMed ID: 39343244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years.
    Faust JS; Kumar A; Shah J; Khadke S; Dani SS; Ganatra S; Sax PE
    Clin Infect Dis; 2023 Nov; 77(9):1257-1264. PubMed ID: 37387690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
    Liu TH; Huang PY; Wu JY; Chuang MH; Hsu WH; Tsai YW; Chang CC; Lai CC
    J Med Virol; 2023 May; 95(5):e28801. PubMed ID: 37218308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19.
    Wu JY; Liu MY; Liu TH; Chuang MH; Hsu WH; Huang PY; Tsai YW; Lai CC
    Int J Antimicrob Agents; 2023 Dec; 62(6):106984. PubMed ID: 37769748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019.
    Ganatra S; Dani SS; Ahmad J; Kumar A; Shah J; Abraham GM; McQuillen DP; Wachter RM; Sax PE
    Clin Infect Dis; 2023 Feb; 76(4):563-572. PubMed ID: 35986628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.
    Geng LN; Bonilla H; Hedlin H; Jacobson KB; Tian L; Jagannathan P; Yang PC; Subramanian AK; Liang JW; Shen S; Deng Y; Shaw BJ; Botzheim B; Desai M; Pathak D; Jazayeri Y; Thai D; O'Donnell A; Mohaptra S; Leang Z; Reynolds GZM; Brooks EF; Bhatt AS; Shafer RW; Miglis MG; Quach T; Tiwari A; Banerjee A; Lopez RN; De Jesus M; Charnas LR; Utz PJ; Singh U
    JAMA Intern Med; 2024 Sep; 184(9):1024-1034. PubMed ID: 38848477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
    Butt AA; Yan P; Shaikh OS
    PLoS One; 2024; 19(6):e0298254. PubMed ID: 38843201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
    Fishman J; Kim Y; Parisé H; Bercaw E; Smith Z
    J Med Econ; 2024; 27(1):1108-1118. PubMed ID: 39155764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia.
    Mamolo C; Welch V; Walter RB; Cappelleri JC; Brockbank J; Cawson M; Knight C; Wilson M
    Pharmacoeconomics; 2021 Jan; 39(1):121-131. PubMed ID: 33236329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis.
    Li H; Xiang H; He B; Zhang Q; Peng W
    J Glob Health; 2023 Jul; 13():06032. PubMed ID: 37469290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.